Vaxxas Gets $20M Injection to Test Needle-Free Vaccines in Humans

Xconomy Boston — 

What’s the worst part of getting vaccinated? Most folks, outside of the anti-vaccination crowd, would probably say the needle prick. A startup named Vaxxas is one of a group of companies trying to get rid of the ouch factor, and today it just got a big round of cash to see if its approach works in human beings.

Vaxxas, a startup with operations in Cambridge, MA, and Australia, has raised a $20 million Series B round to continue developing what it calls the Nanopatch; a method of delivering vaccines through a small skin patch, not a needle. The cash is coming from “new and existing investors.” Vaxxas isn’t disclosing the specific investors in the new round, but its existing backers include OneVentures, Brandon Capital, HealthCare Ventures, and the Medical Research Commercialisation Fund, an investment entity supported by the Australian government.

The raise comes as Vaxxas is hitting the most critical point in its development. Later this year, it’ll finally begin testing its technology in humans. According to CEO David Hoey, that first trial will likely be of a skin patch version of the flu vaccine. If Vaxxas can show that the vaccine can safely elicit a potent immune response, the kind that a traditional vaccine can produce (or ideally a better one), it’ll help validate the company’s plans to apply its technology to vaccines for polio, bacterial infections—even cancer.

“We’re sort of shifting gears,” Hoey says.

Vaxxas started up in 2011, based on work out of Mark Kendall’s lab at Queensland University in Australia. That work led to the Nanopatch: a device, about a square centimeter in size, that looks like sandpaper to the naked eye. The patch is covered with tens of thousands of ultra-tiny spikes that can deliver doses of a vaccine to immune cells just under the skin. It’s administered via a spring-loaded applicator, and is supposed to deliver enough vaccine to induce a potent immune response—despite using one-hundredth the volume of vaccine of the typical injection.

The technology has a few key selling points. First, these patch-loaded vaccines are stable at room temperature because Vaxxas develops special formulations that are dried onto the patch’s little spikes. This sets it apart from most vaccines, which have to be kept cold. That’s not necessarily a big deal in the U.S., which has the so-called “cold chain” infrastructure to keep vaccines refrigerated from manufacturing to shipment to storage at a clinic or hospital. But a slew of developing countries lack such infrastructure, limiting the reach of life-saving immunizations–that’s part of the reason Vaxxas got funding support from the World Health Organization last year to develop a polio vaccine using the Nanopatch, Hoey says.

The second value add is getting rid of the needle and the ouch factor. Hoey says the Nanopatch feels like a “tap” on the skin. And he also claims that delivering a vaccine to the skin, rather than systemically via an injection, is more efficient—“most of the population of immune cells are directly beneath the skin,” he notes—so that should translate to a more potent response.

The approach got the attention of Merck, one of the world’s biggest vaccine makers, in 2012. After Vaxxas closed a $12 million Series A round, the two signed a deal that enabled Merck to tap into Vaxxas’s technology to convert one of its vaccines to skin patch product. It’s a typical licensing deal: Vaxxas got an (undisclosed) upfront fee, and was promised some milestone payments and royalties. Hoey won’t say what the status of that vaccine is or even what it treats (“the relationship is progressing,” he says), but deals like this are how Vaxxas envisions growing and making money. The company isn’t actually developing its own vaccines in-house—a costly, difficult venture for a startup. Rather, Vaxxas is scouting for … Next Page »

Single PageCurrently on Page: 1 2

By posting a comment, you agree to our terms and conditions.

2 responses to “Vaxxas Gets $20M Injection to Test Needle-Free Vaccines in Humans”

  1. Undecider says:

    This is a step towards safer vaccinations. The “anti-vaccination” crowd has legitimate concerns as they do not want to be contaminated with or exposed to dangerous ingredients, adjuvants and preservatives. All of which have been demonstrated as a cause for undesirable adverse reactions. Just read the “insert”! Using a patch can go a long way to limit this exposure.

    My curiosity would be to see a complete list of ingredients that would transfer transdermally. Moreover, any long term studies would be worth reading. In nature, we are exposed to viruses. Not normally viruses plus additives. The safest vaccines would be those that emulate nature the closest. The needle-borne vaccines available to the general public are the least safe because they are practically nothing like what we’d be exposed to on a normal basis. Direct injection into the bloodstream with all the additives is madness.

    Transdermal, comparitively speaking, seems like a lot better option. Let’s hope they don’t spike these with all the usual sterilants and neurologically embolizing agents.

    • ImmuneResponse says:

      If you read this study Undecider, you might be disappointed. Fernando GJP, Chen X, Primero CA, Yukiko SR, Fairmaid EJ, Corbett HJ,
      Frazer IH, Brown LE, Kendall MAF. (2012) Nanopatch targeted delivery of
      both antigen and adjuvant to skin synergistically drives enhanced
      antibody responses. Journal of Controlled Release 159(2), 215-221.